Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Edaravone's Safety Profile in Acute Ischemic Stroke.
Brain Behav
December 2024
Department of Neurology, Zeenat Qureshi Stroke Institute, Jose R. Reyes Memorial Medical Center, Manila, Philippines.
Background: We aimed to evaluate the safety of intravenous edaravone for the treatment of acute ischemic stroke among Filipino patients. The study, categorized as Phase IV, spans from December 2022 to November 2023. The primary objective is to document side effects and serious adverse events during the 14-day edaravone infusion period.
View Article and Find Full Text PDFPharmacokinetics, Pharmacodynamics and Bioavailability of ACM-001.1 (S-Pindolol Benzoate) in Healthy Volunteers.
J Cachexia Sarcopenia Muscle
February 2025
Quotient Sciences, Nottingham, UK.
Background: S-pindolol has metabolic effects of potential benefit in cancer cachexia: reduced catabolism through nonselective β-blockade; increased anabolism through partial β2 receptor agonism; and increased appetite and reduced fatigue through central 5-hydroxytryptamine/serotonin receptor activity. A Phase 2a clinical trial demonstrated that S-pindolol can reverse weight loss and improve fat-free mass in patients with cancer-related weight loss. A comparative phase I bioavailability study of S-pindolol and racemic pindolol was performed to support the development of S-pindolol in cancer cachexia.
View Article and Find Full Text PDFSerious adverse events associated with conservative physical procedures directed towards the cervical spine: A systematic review.
J Bodyw Mov Ther
March 2025
School of Health and Rehabilitation Sciences, University of Queensland, Australia. Electronic address:
Background: Previous reviews on serious adverse events (SAEs) following physical interventions involving the neck have focused on vascular SAEs or those related to cervical manipulation.
Objective: To review the evidence for all serious adverse events associated with any physical cervical procedures and describe SAE characteristics.
Methods: Searches were conducted in PubMed, EMBASE, CINAHL, Scopus, Cochrane, Web of Science and Index to Chiropractic Literature from inception to May 2023 for studies reporting characteristics of SAE following any neck intervention and patient demographics.
A case report of refractory immune thrombocytopenia: Challenges in choice of therapies in resource limiting center.
Int J Surg Case Rep
November 2024
Assistant Professor of Surgery, College of Health Science, Deberetabor University, Debretabor, Ethiopia. Electronic address:
Introduction And Importance: Refractory immune thrombocytopenic purpura (ITP) is a rare but serious condition causing significant morbidity and mortality due to inadequate response to standard treatments, resulting in persistent thrombocytopenia and increased bleeding risk.
Case Presentation: An 18-year-old female patient, diagnosed with ITP two years prior following excessive vaginal bleeding and fatigue, was initially treated with oral prednisolone for two months and discharged in improved condition. Eighteen months after treatment cessation, she presented with recurrent excessive vaginal bleeding, intermittent bilateral nasal bleeding, skin rash, blurred vision, fatigue, tinnitus, vertigo, and intermittent headaches (one-month duration).
Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial.
Lancet Infect Dis
November 2024
Otsuka Pharmaceutical Development & Commercialization, Rockville, MD, USA. Electronic address:
Background: Quabodepistat (formerly OPC-167832) showed potent activity in preclinical studies and in the first stage of an early bactericidal activity study in adults with smear-positive, drug-susceptible pulmonary tuberculosis. Stage 2 of this study was designed to evaluate the safety, tolerability, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both versus rifampicin, isoniazid, ethambutol, and pyrazinamide combination therapy for 14 days.
Methods: Stage 2 of this open-label, active-controlled, randomised, parallel-group study was conducted at two research sites in South Africa in adults (aged 18-64 years) with drug-susceptible pulmonary tuberculosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!